News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Innate Pharma (IPH.PA ): Launch of IND-Enabling Studies for IPH4102


11/8/2013 9:38:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MARSEILLE, France, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announced today that it had selected and qualified the IPH4102 drug candidate for further development.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES